Choi Chan-Bum, Song Jung Soo, Kang Young Mo, Suh Chang Hee, Lee Jisoo, Choe Jung-Yoon, Lee Choong Ki, Shim Seung Cheol, Chung Won Tae, Song Gwan Gyu, Kim Hyun Ah, Ji Jong Dae, Nam Eon Jeong, Park Sung-Hoon, Hong Young Hoon, Sheen Dong Hyuk, Lim Mi Kyoung, Seo Young Ii, Sung Yoon-Kyoung, Kim Tae-Hwan, Lee Jong-Tae, Bae Sang-Cheol
Department of Internal Medicine, The Hospital for Rheumatic Diseases, Hanyang University College of Medicine, Seoul, Republic of Korea.
Clin Ther. 2007 Jul;29(7):1381-9. doi: 10.1016/j.clinthera.2007.07.015.
Combined tramadol/acetaminophen is used to treat pain related to osteoarthritis. However, adverse events (AEs) leading to discontinuation can occur. Dose titration may decrease the risk for AEs.
The aim of this study was to assess the effect of tramadol/acetaminophen titration on the development of AEs leading to treatment discontinuation in patients with knee osteoarthritis.
This 2-week, multicenter, randomized, double-blind, double-dummy, add-on study was conducted at 12 tertiary referral university hospitals in the Republic of Korea. Patients aged 35 to 75 years with knee osteoarthritis receiving a stable dose of NSAIDs and with a daily mean pain-intensity score of > or = 4 on a numeric rating scale (NRS) (0 = no pain to 10 = worst pain) during the 48 hours prior to enrollment were eligible. Patients were randomly assigned to receive 1 tablet of tramadol/acetaminophen 37.5/325 mg QD and 1 placebo BID for 3 days, followed by 1 active tablet BID and 1 placebo QD for 4 days, followed by 1 active tablet TID for 7 days (titration group) or 1 tablet of combined tramadol 37.5 mg/acetaminophen 325 mg TID for 14 days (nontitration group). The primary outcome measure was the rate of treatment discontinuation due to AEs. Secondary outcome measures were time to discontinuation due to AEs, prevalences and characteristics of AEs, decrease from baseline in pain intensity as measured on the NRS, and change in the Korean version of the Western Ontario and McMaster Universities (K-WOMAC) index score (scale: 0 = best to 100 = worst).
A total of 250 patients were enrolled (92.0% female; mean [SD] age, 60.2 [7.8] years; mean [SD] weight, 60.0 [9.2] kg [range, 37.5-90.7 kg]; all Korean). The discontinuation rate was significantly lower in the titration group than in the nontitration group (10.5% vs 26.2%; P < 0.001). The Kaplan-Meier survival curve showed that the rates of discontinuation due to AEs were similar in the 2 groups up to day 2, but thereafter the discontinuation rate was significantly lower in the titration group. The most common AEs were nausea (12.1% and 24.6% in the titration and nontitration groups, respectively; P = 0.008), vomiting (4.0% and 17.2%; P < 0.001), and dizziness (9.7% and 22.1%; P = 0.005). No serious AEs were reported in either group. Tramadol/acetaminophen use was associated with a similar decrease from baseline in pain in both the titration and nontitration groups (mean [SD] Delta: NRS, -1.60 [1.62] vs -1.68 [1.58]; total K-WOMAC, -12.86 [13.73] vs -12.52 [16.58]).
In this population of Korean patients with knee osteoarthritis pain managed with a stable dose of NSAIDs, titration of tramadol/acetaminophen over 12 days was associated with improved tolerability and a significantly lower discontinuation rate compared with nontitration. Both regimens significantly reduced from baseline associated with osteoarthritis.
曲马多/对乙酰氨基酚复方制剂用于治疗骨关节炎相关疼痛。然而,可能会出现导致停药的不良事件(AE)。剂量滴定可能会降低不良事件的风险。
本研究旨在评估曲马多/对乙酰氨基酚滴定对膝骨关节炎患者因不良事件导致治疗停药的影响。
这项为期2周的多中心、随机、双盲、双模拟、附加研究在韩国的12家三级转诊大学医院进行。年龄在35至75岁之间、正在接受稳定剂量非甾体抗炎药治疗、在入组前48小时内数字评分量表(NRS)(0 = 无疼痛至10 = 最严重疼痛)上每日平均疼痛强度评分≥4分的膝骨关节炎患者符合条件。患者被随机分配接受1片曲马多/对乙酰氨基酚37.5/325 mg每日一次和1片安慰剂每日两次,共3天,然后1片活性片每日两次和1片安慰剂每日一次,共4天,随后1片活性片每日三次,共7天(滴定组)或1片曲马多37.5 mg/对乙酰氨基酚325 mg复方制剂每日三次,共14天(非滴定组)。主要结局指标是因不良事件导致的治疗停药率。次要结局指标是因不良事件导致停药的时间、不良事件的发生率和特征、NRS测量的疼痛强度较基线的降低以及韩国版西安大略和麦克马斯特大学骨关节炎指数(K-WOMAC)评分的变化(范围:0 = 最佳至100 = 最差)。
共纳入250例患者(92.0%为女性;平均[标准差]年龄,60.2[7.8]岁;平均[标准差]体重,60.0[9.2]kg[范围,37.5 - 90.7 kg];均为韩国人)。滴定组的停药率显著低于非滴定组(10.5%对26.2%;P < 0.001)。Kaplan-Meier生存曲线显示,在第2天之前,两组因不良事件导致的停药率相似,但此后滴定组的停药率显著更低。最常见的不良事件是恶心(滴定组和非滴定组分别为12.1%和24.6%;P = 0.008)、呕吐(4.0%和17.2%;P < 0.001)和头晕(9.7%和22.1%;P = 0.005)。两组均未报告严重不良事件。曲马多/对乙酰氨基酚的使用在滴定组和非滴定组中与疼痛较基线的相似降低相关(平均[标准差]变化:NRS,-1.60[1.62]对-1.68[1.58];K-WOMAC总分,-12.86[13.73]对-12.52[16.58])。
在这群接受稳定剂量非甾体抗炎药治疗的韩国膝骨关节炎疼痛患者中,与非滴定相比,曲马多/对乙酰氨基酚12天的滴定与耐受性改善和显著更低的停药率相关。两种方案均使与骨关节炎相关的症状较基线显著减轻。